ReviewMolecules (Basel, Switzerland)2015
Glycosaminoglycans and glycomimetics in the central nervous system.
Review in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Nanoparticle-enriched mass spectrometry enables comprehensive plasma proteomics and reveals novel candidates for mild cognitive impairment.Scientific reports · 2026Article
- Quantum Consciousness: A Molecular Perspective Involving Glycoprotein-Tunnelling Hypothesis (GPTH).Current medicinal chemistry · 2026Article
- Investigating Neotenic and Metamorphic Axolotl Brain Complexity: A Stereological and Immunohistochemical Perspective.The Journal of comparative neurology · 2025Article
- Novel Insights into Changes in Gene Expression within the Hypothalamus in Two Asthma Mouse Models: A Transcriptomic Lung-Brain Axis Study.International journal of molecular sciences · 2024Article
- Development of Combinatorial Therapeutics for Spinal Cord Injury using Stem Cell Delivery.Journal of visualized experiments : JoVE · 2024Article
- [Natural history of mucopolysaccharidosis type III in a series of Colombian patients].Revista de neurologia · 2024Article
- Mucopolysaccharidosis type IIIB: a current review and exploration of the AAV therapy landscape.Neural regeneration research · 2024Review
- Glioblastoma Extracellular Vesicle-Specific Peptides Inhibit EV-Induced Neuronal Cytotoxicity.International journal of molecular sciences · 2022Article
- The dynamic brain N-glycome.Glycoconjugate journal · 2022Review
- Neurogenesis as a Tool for Spinal Cord Injury.International journal of molecular sciences · 2022Review
- Age-dependent viscoelastic characterization of rat brain cortex.Brain multiphysics · 2022Article
- Transplantation of Neural Precursors Derived from Induced Pluripotent Cells Preserve Perineuronal Nets and Stimulate Neural Plasticity in ALS Rats.International journal of molecular sciences · 2020Article
- Aberrant glycosylation in schizophrenia: a review of 25 years of post-mortem brain studies.Molecular psychiatry · 2020Review
- The Role of the Microenvironment in Controlling the Fate of Bioprinted Stem Cells.Chemical reviews · 2020Review
- Identification and Functional Assessment of the First Placental Adhesin ofFrontiers in microbiology · 2020Article
- Moving beyond the glial scar for spinal cord repair.Nature communications · 2019Review
- Glycosaminoglycan Compositional Analysis of Relevant Tissues in Zika Virus Pathogenesis and in Vitro Evaluation of Heparin as an Antiviral against Zika Virus Infection.Biochemistry · 2019Article
- The polysialic acid mimetics idarubicin and irinotecan stimulate neuronal survival and neurite outgrowth and signal via protein kinase C.Journal of neurochemistry · 2017Article
- LW-AFC Effects onAging and disease · 2017Article
- Glycosaminoglycans and Their Mimetics.Molecules (Basel, Switzerland) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With recent advances in the construction of synthetic glycans, selective targeting of the extracellular matrix (ECM) as a potential treatment for a wide range of diseases has become increasingly popular. The use of compounds that mimic the structure or bioactive function of carbohydrate structures has been termed glycomimetics. These compounds are mostly synthetic glycans or glycan-binding constructs which manipulate cellular interactions. Glycosaminoglycans (GAGs) are major components of the ECM and exist as a diverse array of differentially sulphated disaccharide units. In the central nervous system (CNS), they are expressed by both neurons and glia and are crucial for brain development and brain homeostasis. The inherent diversity of GAGs make them an essential biological tool for regulating a complex range of cellular processes such as plasticity, cell interactions and inflammation. They are also involved in the pathologies of various neurological disorders, such as glial scar formation and psychiatric illnesses. It is this diversity of functions and potential for selective interventions which makes GAGs a tempting target. In this review, we shall describe the molecular make-up of GAGs and their incorporation into the ECM of the CNS. We shall highlight the different glycomimetic strategies that are currently being used in the nervous system. Finally, we shall discuss some possible targets in neurological disorders that may be addressed using glycomimetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.